Predicting survival and prognosis of postoperative breast cancer brain metastasis: a population-based retrospective analysis

被引:1
作者
Nie Yan [1 ]
Ying Bicheng [1 ]
Lu Zinan [6 ]
Sun Tonghui [1 ]
Sun Gang [1 ]
机构
[1] Department of Breast and Thyroid Surgery
[2] The Affiliated Cancer Hospital of Xinjiang Medical University  3. Urumqi  4. Xinjiang 830011 
[3] Xinjiang Cancer Center/Key Laboratory of Oncology of Xinjiang Uyghur Autonomous Region
[4] China.
基金
中国国家自然科学基金;
关键词
Breast cancer brain metastasis; Nomograms; Overall survival; Surveillance; Survival prediction model;
D O I
暂无
中图分类号
R737.9 [乳腺肿瘤];
学科分类号
100214 ;
摘要
Background: Breast cancer is one of the most common cancer in women and a proportion of patients experiences brain metastases with poor prognosis. The study aimed to construct a novel predictive clinical model to evaluate the overall survival (OS) of patients with postoperative brain metastasis of breast cancer (BCBM) and validate its effectiveness.Methods: From 2010 to 2020, a total of 310 female patients with BCBM were diagnosed in The Affiliated Cancer Hospital of Xinjiang Medical University, and they were randomly assigned to the training cohort and the validation cohort. Data of another 173 BCBM patients were collected from the Surveillance, Epidemiology, and End Results Program (SEER) database as an external validation cohort. In the training cohort, the least absolute shrinkage and selection operator (LASSO) Cox regression model was used to determine the fundamental clinical predictive indicators and the nomogram was constructed to predict OS. The model capability was assessed using receiver operating characteristic, C-index, and calibration curves. Kaplan-Meier survival analysis was performed to evaluate clinical effectiveness of the risk stratification system in the model. The accuracy and prediction capability of the model were verified using the validation and SEER cohorts.Results: LASSO Cox regression analysis revealed that lymph node metastasis, molecular subtype, tumor size, chemotherapy, radiotherapy, and lung metastasis were statistically significantly correlated with BCBM. The C-indexes of the survival nomogram in the training, validation, and SEER cohorts were 0.714, 0.710, and 0.670, respectively, which showed good prediction capability. The calibration curves demonstrated that the nomogram had great forecast precision, and a dynamic diagram was drawn to increase the maneuverability of the results. The Risk Stratification System showed that the OS of low-risk patients was considerably better than that of high-risk patients (P < 0.001).Conclusion: The nomogram prediction model constructed in this study has a good predictive value, which can effectively evaluate the survival rate of patients with postoperative BCBM.
引用
收藏
相关论文
共 19 条
  • [1] Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases
    Parkes, Amanda
    Warneke, Carla L.
    Clifton, Katherine
    Al-Awadhi, Aydah
    Oke, Oluchi
    Pestana, Roberto Carmagnani
    Alhalabi, Omar
    Litton, Jennifer K.
    Hortobagyi, Gabriel N.
    [J]. ONCOLOGIST, 2018, 23 (11) : 1282 - 1288
  • [2] Thirty-Year Trends of Survival and Time-Varying Effects of Prognostic Factors in Patients With Metastatic Breast Cancer A Single Institution Experience
    Rogoz, Bianca
    de l'Aulnoit, Agathe Houze
    Duhamel, Alain
    de l'Aulnoit, Denis Houze
    [J]. CLINICAL BREAST CANCER, 2018, 18 (03) : 246 - 253
  • [3] Breast cancer brain metastases: biology and new clinical perspectives..[J].Witzel Isabell;Oliveira-Ferrer Leticia;Pantel Klaus;Müller Volkmar;Wikman Harriet.Breast cancer research : BCR.2016, 1
  • [4] αB-crystallin Expression in Breast Cancer is Associated with Brain Metastasis..[J].Voduc K David;Nielsen Torsten O;Perou Charles M;Harrell J Chuck;Fan Cheng;Kennecke Hagen;Minn Andy J;Cryns Vincent L;Cheang Maggie C U.NPJ breast cancer.2015, Supp
  • [5] Pattern of metastasis and outcome in patients with breast cancer
    Gerratana, L.
    Fanotto, V.
    Bonotto, M.
    Bolzonello, S.
    Minisini, A. M.
    Fasola, G.
    Puglisi, F.
    [J]. CLINICAL & EXPERIMENTAL METASTASIS, 2015, 32 (02) : 125 - 133
  • [6] Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
    Krop, I. E.
    Lin, N. U.
    Blackwell, K.
    Guardino, E.
    Huober, J.
    Lu, M.
    Miles, D.
    Samant, M.
    Welslau, M.
    Dieras, V.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (01) : 113 - 119
  • [7] Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis
    Niikura, Naoki
    Hayashi, Naoki
    Masuda, Norikazu
    Takashima, Seiki
    Nakamura, Rikiya
    Watanabe, Ken-ichi
    Kanbayashi, Chizuko
    Ishida, Mayumi
    Hozumi, Yasuo
    Tsuneizumi, Michiko
    Kondo, Naoto
    Naito, Yoichi
    Honda, Yayoi
    Matsui, Akira
    Fujisawa, Tomomi
    Oshitanai, Risa
    Yasojima, Hiroyuki
    Tokuda, Yutaka
    Saji, Shigehira
    Iwata, Hiroji
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2014, 147 (01) : 103 - 112
  • [8] Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
    Bachelot, Thomas
    Romieu, Gilles
    Campone, Mario
    Dieras, Veronique
    Cropet, Claire
    Dalenc, Florence
    Jimenez, Marta
    Le Rhun, Emilie
    Pierga, Jean-Yves
    Goncalves, Anthony
    Leheurteur, Marianne
    Domont, Julien
    Gutierrez, Maya
    Cure, Herve
    Ferrero, Jean-Marc
    Labbe-Devilliers, Catherine
    [J]. LANCET ONCOLOGY, 2013, 14 (01) : 64 - 71
  • [9] A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases
    Tsao, May
    Xu, Wei
    Sahgal, Arjun
    [J]. CANCER, 2012, 118 (09) : 2486 - 2493
  • [10] Management of Patients with Brain Metastases Receiving Trastuzumab Treatment for Metastatic Breast Cancer
    Witzela, Isabell
    Kantelhardt, Eva Johanna
    Milde-Langosch, Karin
    Ihnen, Maike
    Zeitz, Julia
    Harbeck, Nadia
    Jaenicke, Fritz
    Mueller, Volkmar
    [J]. ONKOLOGIE, 2011, 34 (06): : 304 - 308